RxDoctor Payments DataLook up a doctor →

Takeshi Seto, MD

Internal Medicine · Ottawa, KSNPI 1154323160

Payments from drug & device makers

$7,103in general payments, 2019–2025

Across 433 payments — averaging $16.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Boehringer Ingelheim$738
  • Sunovion Pharmaceuticals Inc.$642
  • GSK$485
  • Sanofi$349
  • Genentech USA, Inc.$340
  • plus $3K from 47 others

What the payments were for

  • Food & beverage$7,03799%
  • Education$661%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,103 in reported general payments places this provider in the 90th percentile of 705 internal medicine providers in Kansas.

See all internal medicine providers in Kansas

Medicare billing

Part B allowed, 2024
$6,464
Medicare patients
79
Services billed
125

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter278$248,983
Fasenra PenBenralizumab13$75,270
Breztri AerosphereBudesonide/Glycopyr/Formoterol79$61,863
EliquisApixaban90$60,707
OzempicSemaglutide48$44,442
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr78$37,704
Stiolto RespimatTiotropium Br/Olodaterol Hcl28$34,188
JardianceEmpagliflozin52$29,782
Breo ElliptaFluticasone/Vilanterol44$28,115
JanuviaSitagliptin Phosphate17$15,005
MyrbetriqMirabegron26$11,782
Tresiba Flextouch U-200Insulin Degludec22$10,509
Albuterol Sulfate HfaAlbuterol Sulfate267$8,632
Montelukast Sodium850$7,724
Tresiba Flextouch U-100Insulin Degludec11$7,157

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$485$314,802400 claims
Boehringer IngelheimStiolto Respimat, Jardiance$738$63,97080 claims
AstraZenecaBreztri Aerosphere$1,295$61,86379 claims
PfizerEliquis$83$60,70790 claims
Novo NordiskOzempic$240$44,44248 claims
MerckJanuvia$14$15,00517 claims
AbbVieSynthroid$99$1,88033 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 705 internal medicine providers in Kansas.

Other internal medicine in Ottawa

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →